Sastasundar Ventures Limited (SASTASUNDR) AI Stock Analysis

• Market Cap: ₹8.93B
• Dividend Yield: N/A
• Average Volume (3M): 1.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -14.64%
• EPS Growth: -355.01%
• Country: IN
• Employees: 941
• Sector: Consumer Defensive
• Sector Strength: 67
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 7.52
• Shares Outstanding: 31,810,500
• 10 Day Avg. Volume: 1,308
• 30 Day Avg. Volume: 1,225
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹275.00
• Price Target Upside: -6.22% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: ₹275.00 ▼(-6.22% Downside)

Sastasundar Ventures Limited's overall stock score is primarily impacted by its weak financial performance and valuation concerns. The company's declining revenues and persistent losses are significant risks. Technical analysis provides mixed signals, with no strong momentum. The absence of earnings call data and corporate events limits additional insights.

Sastasundar Ventures Limited Business Overview & Revenue Model

Company Description

Sastasundar Ventures Limited (SASTASUNDR) is an Indian company operating predominantly in the healthcare and wellness sectors. It is primarily engaged in the online distribution of pharmaceutical and healthcare products through its digital platform. The company aims to provide affordable and accessible healthcare solutions by leveraging technology to streamline the supply chain and reduce costs for consumers. Sastasundar's core services include the online retailing of medicines, health supplements, personal care products, and other wellness-related items.

How the Company Makes Money

Sastasundar Ventures Limited generates revenue through its e-commerce platform, which facilitates the sale of pharmaceutical and healthcare products directly to consumers. The company makes money by purchasing products from manufacturers or authorized distributors at wholesale prices and selling them at a retail margin. Additionally, Sastasundar may earn revenue from partnerships with healthcare providers, pharmacies, and wellness brands looking to reach a broader customer base through its platform. The company's business model focuses on efficiency in supply chain management and cost reduction to offer competitive pricing, thus attracting a larger customer base and driving sales growth.

Sastasundar Ventures Limited Financial Statement Overview

Summary

Sastasundar Ventures Limited shows declining revenues and persistent losses, undermining profitability. The balance sheet is stable with low debt, but negative margins and cash flow issues highlight operational inefficiencies. Financial stability requires improvement in cash generation and operational performance.

Income Statement

Sastasundar Ventures Limited has shown significant volatility in revenue and profitability. The company experienced a notable decline in revenue from 2024 to 2025, with a decrease from 13.56 billion to 10.89 billion. The net profit margin has been negative, reflecting recurring losses, with net income dropping from a modest profit in 2024 to a significant loss in 2025. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies. A key strength is the prior year revenue growth between 2023 and 2024, but consistent profitability remains a challenge.

Balance Sheet

The company's balance sheet demonstrates moderate strength, with a favorable equity ratio due to a substantial stockholders' equity of 6.70 billion against total assets of 9.74 billion as of 2025. The debt-to-equity ratio is low, signifying minimal leverage, which reduces financial risk. However, the return on equity is negative due to net losses, indicating that the company is not effectively generating returns on its equity base.

Cash Flow

Cash flow analysis indicates challenges, with negative operating cash flow in 2025, pointing to struggles in generating cash from core operations. Free cash flow has also decreased significantly, reflecting negative growth and potential liquidity issues. Positive free cash flow from 2024 did not sustain, which impacts the company's ability to fund operations without external financing.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	10.90B	13.56B	10.38B	6.30B	5.46B
Gross Profit	721.21M	1.20B	711.54M	445.35M	513.28M
EBITDA	-1.87B	-203.51M	-1.13B	11.22B	-109.58M
Net Income	-911.67M	88.83M	-722.11M	6.27B	-104.01M
Balance Sheet
Total Assets	9.74B	11.50B	12.06B	12.78B	2.93B
Cash, Cash Equivalents and Short-Term Investments	124.44M	665.40M	2.08B	2.12B	124.49M
Total Debt	9.19M	38.83M	93.25M	18.53M	152.02M
Total Liabilities	1.10B	1.50B	2.12B	1.84B	634.32M
Stockholders Equity	6.70B	7.62B	7.53B	8.27B	2.00B
Cash Flow
Free Cash Flow	-276.65M	239.34M	-1.31B	-2.12B	-314.92M
Operating Cash Flow	-173.09M	381.65M	-1.12B	-2.07B	-305.08M
Investing Cash Flow	-11.34M	-339.27M	1.24B	2.20B	213.71M
Financing Cash Flow	-4.43M	-23.52M	-18.33M	-114.22M	37.26M

Sastasundar Ventures Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 293.25
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SASTASUNDR, the sentiment is Positive. The current price of 293.25 is above the 20-day moving average (MA) of 288.91, above the 50-day MA of 286.90, and above the 200-day MA of 283.02, indicating a neutral trend. The MACD of -1.54 indicates Positive momentum. The RSI at 49.80 is Neutral, neither overbought nor oversold. The STOCH value of 30.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SASTASUNDR.

Sastasundar Ventures Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$21.01B	14.53	-7.26%	3.13%	3.36%	-7.91%
MEDPLUS	62 Neutral	₹97.67B	54.58		―	6.18%	134.57%
SASTASUNDR	46 Neutral	₹8.93B	―		―	-14.64%	-355.01%